IRA Implications Will Factor Significantly In Deal Strategy In 2023
PwC Expects More Deals, But Affected By IRA
A pair of new PwC reports project a more robust M&A environment in 2023, but questions about the impact of the Inflation Reduction Act are already affecting biopharma business development strategies.
